Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. Neelapu on the Safety Profile of ALLO-501 Plus ALLO-647 in R/R B-Cell Lymphomas

June 29th 2020

Sattva Neelapu, MD, discusses the safety profile of ALLO-501 in combination with ALLO-647 in patients with relapsed/refractory large B-cell lymphoma or follicular lymphoma.

Belantamab Mafodotin Induces Responses in Relapsed/Refractory Myeloma, But Calls for Multidisciplinary Approach

June 29th 2020

Sagar Lonial, MD, FACP, discusses the updated data from DREAMM-2 with belantamab mafodotin, associated toxicities to be aware of, and future directions for research.

Dr. Costello on Determining Proper Dosing of Carfilzomib in Relapsed/Refractory Myeloma

June 26th 2020

Caitlin Costello, MD, discusses proper dosing of carfilzomib in relapsed/refractory multiple myeloma.

Leonard Leads Discussion on Latest Developments in Leukemias and Lymphomas

June 26th 2020

Data in Richter’s transformation, Hodgkin lymphoma, Waldenström macroglobulinemia, and indolent lymphoma were presented at the 2020 ASCO Virtual Scientific Program, and although not entirely practice changing, are deserving of attention.

Dr. Richardson on the Next Steps With CC-92480 Research in Relapsed/Refractory Multiple Myeloma

June 26th 2020

Paul G. Richardson, MD, discusses the next steps ​with the investigational cereblon E3 ligase modulator agent CC-92480 research in ​relapsed/refractory multiple myeloma.

Dr. DiNardo on the Rationale for the Pooled Analysis Evaluating Venetoclax in AML

June 26th 2020

Courtney DiNardo, MD, MSCE, discusses the rational​e for a pooled analysis evaluating venetoclax in acute myeloid leukemia.

Dr. Sharman on ​the Challenges of Adjust​ing Treatment Based on MRD Status in CLL

June 26th 2020

Jeff P. Sharman, MD, discusses the challenges of adjusting treatments based on minimal residual disease status in high-risk chronic lymphocytic leukemia.

New Strategies for Targeting CD38 in Multiple Myeloma Take Root

June 26th 2020

During the past 5 years, therapies targeting CD38, a protein highly expressed on the surface of plasma cells, have helped fuel the rapidly growing treatment options for patients with multiple myeloma.

Dr. Kuruvilla on the Safety of Pembrolizumab in Classical Hodgkin Lymphoma

June 25th 2020

John Kuruvilla, MD, FRCPC, discusses the safety of pembrolizumab (Keytruda) versus brentuximab vedotin in classical Hodgkin lymphoma.

Dr. Berdeja on Next Steps With JNJ-4528 in Relapsed/Refractory Myeloma

June 25th 2020

Jesus G. Berdeja, MD, discusses next steps for the phase 2 CARTITUDE-1 study with JNJ-4528 in relapsed/refractory myeloma.

Hill Welcomes Addition of Selinexor to DLBCL Armamentarium

June 25th 2020

The recent approval of selinexor (Xpovio) provides a novel treatment for patients with diffuse large B-cell lymphoma who have exhausted available options.

Dr. Usmani on Current Challenges in High-Risk Multiple Myeloma

June 25th 2020

Saad Z. Usmani, MD, FACP, discusses current challenges in patients with high-risk multiple myeloma.

Dr. Ghosh on Efficacy Results from the Phase 2 PILOT trial in Non-Hodgkin Lymphoma

June 25th 2020

Nilanjan Ghosh, MD, PhD, discusses efficacy results from the phase 2 PILOT trial in patients with high-risk relapsed/refractory B-cell non-Hodgkin lymphoma.

Loncastuximab Tesirine Shows Synergistic Activity With Ibrutinib in DLBCL, MCL

June 24th 2020

The combination of the antibody­-drug conjugate loncastuximab tesirine and ibrutinib showed early clinical activity with manageable toxicity in patients with relapsed/refractory diffuse large B-cell lymphoma and mantle cell lymphoma.

FDA Lifts Partial Clinical Hold on TELLOMAK Trial With Lacutamab in Advanced T-Cell Lymphomas

June 24th 2020

The FDA has lifted a partial clinical hold that had been placed on the phase 2 TELLOMAK trial, which is examining the safety and efficacy of lacutamab in patients with advanced T-cell lymphoma.

Axi-Cel Elicits Encouraging Activity in Indolent Follicular Lymphoma, Marginal Zone Lymphoma

June 24th 2020

Caron Jacobson, MD, discusses the initial ZUMA-5 findings and the next steps with axicabtagene ciloleucel in follicular lymphoma and marginal zone lymphoma.

Dr. Kuruvilla on the Broad Utility of Pembrolizumab in Hodgkin Lymphoma

June 24th 2020

John Kuruvilla, MD, FRCPC, discusses the broad utility of pembrolizumab in Hodgkin lymphoma.

Dr. Hill on the Safety Profile of Selinexor in Relapsed/Refractory DLBCL

June 24th 2020

Brian T. Hill, MD, PhD, discusses the safety profile of selinexor in relapsed/refractory diffuse large B-cell lymphoma.

Axi-Cel Retreatment Demonstrates Clinical Efficacy in Large B-Cell Lymphoma

June 24th 2020

Findings from an exploratory analysis of the phase 1/2 ZUMA-1 trial demonstrated clinical efficacy in patients with relapsed/refractory large B-cell lymphoma who were retreated with the CAR T-cell therapy axicabtagene ciloleucel.

Expanded FDA Label Sought for Ibrutinib/Rituximab With Long-Term Data in Waldenström Macroglobulinemia

June 23rd 2020

A supplemental new drug application has been submitted to the FDA for review for the use of ibrutinib in combination with rituximab as a treatment for patients with Waldenström macroglobulinemia.

NEXT PAGE
PREVIOUS PAGE